TY - JOUR
T1 - CD73 inhibition shifts cardiac macrophage polarization toward a microbicidal phenotype and ameliorates the outcome of experimental chagas cardiomyopathy
AU - Ponce, Nicolás Eric
AU - Sanmarco, Liliana Maria
AU - Eberhardt, Natalia
AU - Garćia, Mónica Cristina
AU - Rivarola, Héctor Walter
AU - Cano, Roxana Carolina
AU - Aoki, Maria Pilar
N1 - Publisher Copyright:
Copyright © 2016 by The American Association of Immunologists, Inc.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Increasing evidence demonstrates that generation of extracellular adenosine fromATP, which is hydrolyzed by theCD39/CD73 enzyme pair, attenuates the inflammatory response and deactivates macrophage antimicrobial mechanisms. Although CD73 is emerging as a critical pathway and therapeutic target in cardiovascular disorders, the involvement of this ectonucleotidase during myocardial infection has not been explored. Using a murine model of infection with Trypanosoma cruzi, the causal agent of Chagas cardiomyopathy, we observed a sudden switch from the classical M1 macrophage (microbicidal) phenotype toward an alternative M2 (repairing/antiinflammatory) phenotype that occurred within the myocardium very shortly after BALB/c mice infection. The observed shift inM1/M2 rate correlated with the cardiac cytokine milieu. Considering that parasite persistence within myocardium is a necessary and sufficient condition for the development of the chronic myocarditis, we hypothesized that CD73 activity may counteract cardiac macrophage microbicidal polarization, rendering the local immune response less effective. In fact, a transient treatment with a specific CD73 inhibitor (adenosine 59-a,b-methylene-diphosphate) enhanced the microbicidal M1 subset predominance, diminished IL-4-and IL-10-producing CD4+ T cells, promoted a proinflammatory cytokine milieu, and reduced parasite load within the myocardium during the acute phase. As a direct consequence of these events, there was a reduction in serum levels of creatine kinase muscle-brain isoenzyme, a myocardial-specific injury marker, and an improvement in the electrocardiographic characteristics during the chronic phase. Our results demonstrate that this purinergic system drives the myocardial immune response postinfection and harbors a promising potential as a therapeutic target.
AB - Increasing evidence demonstrates that generation of extracellular adenosine fromATP, which is hydrolyzed by theCD39/CD73 enzyme pair, attenuates the inflammatory response and deactivates macrophage antimicrobial mechanisms. Although CD73 is emerging as a critical pathway and therapeutic target in cardiovascular disorders, the involvement of this ectonucleotidase during myocardial infection has not been explored. Using a murine model of infection with Trypanosoma cruzi, the causal agent of Chagas cardiomyopathy, we observed a sudden switch from the classical M1 macrophage (microbicidal) phenotype toward an alternative M2 (repairing/antiinflammatory) phenotype that occurred within the myocardium very shortly after BALB/c mice infection. The observed shift inM1/M2 rate correlated with the cardiac cytokine milieu. Considering that parasite persistence within myocardium is a necessary and sufficient condition for the development of the chronic myocarditis, we hypothesized that CD73 activity may counteract cardiac macrophage microbicidal polarization, rendering the local immune response less effective. In fact, a transient treatment with a specific CD73 inhibitor (adenosine 59-a,b-methylene-diphosphate) enhanced the microbicidal M1 subset predominance, diminished IL-4-and IL-10-producing CD4+ T cells, promoted a proinflammatory cytokine milieu, and reduced parasite load within the myocardium during the acute phase. As a direct consequence of these events, there was a reduction in serum levels of creatine kinase muscle-brain isoenzyme, a myocardial-specific injury marker, and an improvement in the electrocardiographic characteristics during the chronic phase. Our results demonstrate that this purinergic system drives the myocardial immune response postinfection and harbors a promising potential as a therapeutic target.
UR - https://www.scopus.com/pages/publications/84979539146
U2 - 10.4049/jimmunol.1600371
DO - 10.4049/jimmunol.1600371
M3 - Article
C2 - 27335499
AN - SCOPUS:84979539146
SN - 0022-1767
VL - 197
SP - 814
EP - 823
JO - Journal of Immunology
JF - Journal of Immunology
IS - 3
ER -